4571 - 4580 of 7915 Results
Title
Year
- Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia2020OPENTitle: Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementiaJournal Name: Nature MedicinePublisher: Springer Science and Business Media LLCVol: 26Issue #: 3Start Page: 379End Page: 386Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/s41591-020-0755-1Best OA location URL: https://discovery.ucl.ac.uk/10093347/3/Zetterberg_Janelidze.pdfCitation Count: 778
-
RESTRICTEDTitle: Social Impact of Connected Landmark Lighting: A Social Sensing ApproachJournal Name: IEEE Internet of Things MagazinePublisher: Institute of Electrical and Electronics Engineers (IEEE)Vol: 3Issue #: 1Start Page: 64End Page: 67Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1109/iotm.0001.1900088Citation Count: 1
-
OPENTitle: Three-Plane–assembled Deep Learning Segmentation of GliomasJournal Name: Radiology: Artificial IntelligencePublisher: Radiological Society of North America (RSNA)Vol: 2Issue #: 2Start Page: e190011End Page: e190011Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1148/ryai.2020190011Best OA location URL: https://pubs.rsna.org/doi/pdf/10.1148/ryai.2020190011Citation Count: 23
-
RESTRICTEDTitle: β-adrenoreceptors and the risk of Parkinson's diseaseJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 3Start Page: 247End Page: 254Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(19)30400-4Citation Count: 46
- An Overview of Crucial Dietary Substances and Their Modes of Action for Prevention of Neurodegenerative Diseases2020RESTRICTEDTitle: An Overview of Crucial Dietary Substances and Their Modes of Action for Prevention of Neurodegenerative DiseasesJournal Name: CellsPublisher: MDPI AGVol: 9Issue #: 3Start Page: 576End Page: 576Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.3390/cells9030576Best OA location URL: https://www.mdpi.com/2073-4409/9/3/576/pdf?version=1585198756Citation Count: 25
- Outcome measurement in functional neurological disorder: a systematic review and recommendations2020RESTRICTEDTitle: Outcome measurement in functional neurological disorder: a systematic review and recommendationsJournal Name: Journal of Neurology, Neurosurgery & PsychiatryPublisher: BMJVol: 91Issue #: 6Start Page: 638End Page: 649Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-ncDOI - Digital Object Identifier: 10.1136/jnnp-2019-322180Best OA location URL: https://jnnp.bmj.com/content/jnnp/91/6/638.full.pdfCitation Count: 82
- Personalized prediction of depression in patients with newly diagnosed Parkinson's disease: A prospective cohort study2020RESTRICTEDTitle: Personalized prediction of depression in patients with newly diagnosed Parkinson's disease: A prospective cohort studyJournal Name: Journal of Affective DisordersPublisher: Elsevier BVVol: 268Issue #:Start Page: 118End Page: 126Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.jad.2020.02.046Citation Count: 21
- Selective Fluorogenic β-Glucocerebrosidase Substrates for Convenient Analysis of Enzyme Activity in Cell and Tissue Homogenates2020OPENTitle: Selective Fluorogenic β-Glucocerebrosidase Substrates for Convenient Analysis of Enzyme Activity in Cell and Tissue HomogenatesJournal Name: ACS Chemical BiologyPublisher: American Chemical Society (ACS)Vol: 15Issue #: 4Start Page: 824End Page: 829Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/acschembio.9b01044Best OA location URL: https://eprints.whiterose.ac.uk/159502/1/acschembio.9b01044.pdfCitation Count: 6
- Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide2020OPENTitle: Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and SafinamideJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 7Issue #: 3Start Page: 343End Page: 345Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.12921Best OA location URL: https://movementdisorders.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.12921Citation Count: 210
- Contingent negative variation: a biomarker of abnormal attention in functional movement disorders2020OPENTitle: Contingent negative variation: a biomarker of abnormal attention in functional movement disordersJournal Name: European Journal of NeurologyPublisher: WileyVol: 27Issue #: 6Start Page: 985End Page: 994Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1111/ene.14189Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ene.14189Citation Count: 14